

July 23, 2021

Corporate Relationship Department  
BSE Limited, PJ Towers, Dalal Street,  
Mumbai- 400001

Dear Sirs

**Sub: Unaudited Financial Results and Limited Review Report for the quarter ended June 30, 2021-  
Outcome of the Board meeting**

**Ref: 1) Regulation 33 of SEBI (LODR) Regulations 2015  
2) Script Code: 526783**

With reference to the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform that, as required in terms of Regulation 30, 33 and other applicable provisions of Listing Regulations, the Board of Directors of the company at its meeting held on July 23, 2021 commenced at 12.15 P.M and concluded at 2.15 P.M have inter alia transacted the following businesses:

- 1) Approved the Un-audited financial results of the Company for the quarter ended June 30, 2021. Copies of the Un-audited Financial Results and Limited Review Report issued by the Statutory Auditors of the company for the quarter is enclosed as **Annexure-I**
- 2) The Company has made arrangement for release of the Un-audited Financial results for the quarter ended June 30, 2021 in the newspaper as per the requirement of the SEBI (LODR) Regulation, 2015.

Kindly take the above information on record.

Thanking you,

Yours sincerely,

**For Dr. Agarwal's Eye Hospital Limited**



**Jolly H Jivani**  
Company Secretary and Compliance Officer



**Dr. Agarwal's Eye Hospital Ltd.**

**Regd. & Corporate Office :**

3rd Floor, Buhari Towers, No.4, Moores Road, off Greams Road, Near Asan Memorial School, Chennai - 600 006.

Tel. : +91 44 4378 7777 | +91 44 4378 7778 | CIN : L85110TN1994PLC027366 | GST No. : 33AAACD2373G1Z2

Email : [info@dragarwal.com](mailto:info@dragarwal.com) | Website : [www.dragarwal.com](http://www.dragarwal.com)



Dr. Agarwal's Eye Hospital Limited  
CIN : L85110TN1994PLC027366

Regd Office: 3rd Floor, Buhari Towers, No. 4, Moores Road, Off Grems Road, Chennai - 600 006  
Phone No. 91-44-39916669 Website : www.dragarwal.com E-mail : investor@dragarwal.com  
Statement of Unaudited Financial Results for the Quarter Ended 30 June 2021

(Amount Rs. in Lakhs except earnings per share data)

S.No.	Particulars	Quarter Ended			Year Ended
		30-Jun-21	31-Mar-21	30-Jun-20	31-Mar-21
		Unaudited	(Refer Note 2)	Unaudited	Audited
<b>1</b>	<b>Income</b>				
	(a) Revenue from Operations	3,087.15	5,171.42	1,501.58	13,980.90
	(b) Other Income	32.06	42.38	28.66	80.63
	<b>Total Income</b>	<b>3,119.21</b>	<b>5,213.80</b>	<b>1,530.24</b>	<b>14,061.53</b>
<b>2</b>	<b>Expenses</b>				
	(a) Purchase of Stock-in-Trade	380.10	617.21	168.55	1,508.33
	(b) Changes in Inventories of Stock-in-Trade - (Increase) / Decrease	(0.33)	(31.36)	54.36	116.33
	(c) Surgical Lens including other consumables	324.54	616.82	165.73	1,625.48
	(d) Consultancy Charges	564.89	691.32	407.41	2,205.06
	(e) Employee Benefit Expenses	883.28	885.59	754.54	3,217.14
	(f) Finance Costs	144.36	166.76	138.05	634.74
	(g) Depreciation and Amortisation Expense	503.77	476.73	493.97	1,909.95
	(h) Rent	53.11	86.69	69.07	317.81
	(i) Other Expenses	362.75	721.18	304.20	1,953.41
	<b>Total Expenses</b>	<b>3,216.47</b>	<b>4,230.94</b>	<b>2,555.88</b>	<b>13,488.25</b>
<b>3</b>	<b>Profit / (Loss) before Exceptional Items and Tax (1-2)</b>	<b>(97.26)</b>	<b>982.86</b>	<b>(1,025.64)</b>	<b>573.28</b>
<b>4</b>	Exceptional Items	-	-	-	-
<b>5</b>	<b>Profit / (Loss) before Tax (3-4)</b>	<b>(97.26)</b>	<b>982.86</b>	<b>(1,025.64)</b>	<b>573.28</b>
<b>6</b>	Tax Expense				
	- Current Tax	-	258.80	-	258.80
	- Tax relating to earlier years	-	563.78	-	563.78
	- Deferred Tax	(24.94)	(14.99)	(264.73)	(105.44)
<b>7</b>	<b>Net Profit / (Loss) after tax for the period (5-6)</b>	<b>(72.32)</b>	<b>175.27</b>	<b>(760.91)</b>	<b>(143.86)</b>
<b>8</b>	<b>Other Comprehensive Income</b>				
	(a) Items that will not be reclassified to the Statement of Profit and Loss				
	- Actuarial (loss) / gain on defined benefit obligation	0.02	22.12	-	0.07
	- Tax on items that will not be reclassified to the Statement of Profit and Loss	(0.01)	(5.52)	-	(0.02)
	(b) Items that will be reclassified to the Statement of Profit and Loss	-	-	-	-
	<b>Total Other Comprehensive Income / (Loss) (net of tax)</b>	<b>0.01</b>	<b>16.60</b>	<b>-</b>	<b>0.05</b>
<b>9</b>	<b>Total Comprehensive Income / (Loss) (7+8)</b>	<b>(72.31)</b>	<b>191.87</b>	<b>(760.91)</b>	<b>(143.81)</b>
<b>10</b>	Paid-up equity share capital (Face value Rs.10/- each)	470.00	470.00	470.00	470.00
<b>11</b>	Reserves (Other Equity)				4,996.28
<b>12</b>	Earnings Per Equity Share (EPS) (Face value of Rs.10/- each)				
	(a) Basic	(1.54)	3.73	(16.19)	(3.06)
	(b) Diluted	(1.54)	3.73	(16.19)	(3.06)
		(not Annualised)	(not Annualised)	(not Annualised)	(Annualised)

**Notes:**

- The above unaudited financial results have been reviewed by the Audit Committee, approved and taken on record by the Board of Directors in their Meeting held on 23 July 2021. The above results for the quarter ended 30 June 2021 has also been subject to limited review by the Statutory Auditors of the Company.
- The figures for the quarter ended 31 March 2021 are the balance figures between the audited figures for the year ended 31 March 2021 and the unaudited year to date figures for the nine months ended 31 December 2020, which were subjected to limited review by the Statutory Auditors.
- The Company operates in a single segment i.e. "Eye Care related sales and services" and hence, does not have any additional disclosures to be made under Ind AS 108 - Operating Segments.
- The Company's operations for the quarter ended 30 June 2021 and 30 June 2020 were impacted on account of the outbreak of COVID-19 pandemic. The results for the quarter are, therefore, not comparable with those of the previous periods.
- The Company has considered internal and certain external sources of information including credit reports, economic forecasts and industry reports up to the date of approval of these financial results in determining the impact on various elements of these financial results relating to COVID-19 pandemic. The Company has used the principles of prudence in applying judgments, estimates and assumptions including sensitivity analysis and based on the current estimates, the Company expects to fully recover the carrying amount of trade receivables and right-of-use asset. The eventual outcome of impact of the global health pandemic may be different from those estimated as on the date of approval of these financial results.
- The Code on Wages 2019 and Code on Social Security 2020 "the Codes" relating to employee compensation and post-employment benefits received the Presidential Assent in September 2020 and the Code has been published in the Official Gazette. However, the date on which the Code will come into effect has not been notified. The Company will assess the impact of the Code when it comes into effect and will record any related impact in the period when the Code becomes effective.

Place : Chennai  
Date : 23 July 2021



By order of the Board

Dr. Amar Agarwal  
Chairman & Managing Director  
DIN No. 00435684



Dr. Agarwal's Eye Hospital Limited  
CIN : L85110TN1994PLC027366  
Regd Office: 3rd Floor, Buhari Towers, No.4, Moores Road, Off Greams Road, Chennai - 600 006  
Phone No. 91-44-39916669 Website : www.dragarwal.com E-mail : investor@dragarwal.com

(Amount in Rs. Lakhs)

Statement of Unaudited Financial Results for the Quarter Ended 30 June 2021

Particulars	Quarter Ended 30 June 2021	Quarter Ended 31 March 2021	Quarter Ended 30 June 2020	For the Year Ended 31 March 2021 (Audited)
Revenue from Operations	3,087.15	5,171.42	1,501.58	13,980.90
Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items )	(97.26)	982.86	(1,025.64)	573.28
Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary items)	(97.26)	982.86	(1,025.64)	573.28
Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items)	(72.32)	175.27	(760.91)	(143.86)
Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	(72.31)	191.87	(760.91)	(143.81)
Paid-up Equity Share Capital (Face Value of Rs.10/- each)	470.00	470.00	470.00	470.00
Reserves (Other Equity)	-	-	-	4,996.28
Earnings Per Share (for continuing and discontinued operations) (Face Value of Rs. 10/- each):				
(a) Basic	(1.54)	3.73	(16.19)	(3.06)
(b) Diluted	(1.54)	3.73	(16.19)	(3.06)
	(not Annualised)	(not Annualised)	(not Annualised)	(Annualised)

**Notes:**

1) The above is an extract of the detailed format of Quarterly Unaudited Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Unaudited Financial Results is available on the Stock Exchange website (www.bseindia.com) and on the Company's website (www.dragarwal.com)

2) The Company's operations for the quarter ended 30 June 2021 and 30 June 2020 were impacted on account of the outbreak of COVID-19 pandemic. The results for the quarter are, therefore, not comparable with those of the previous periods.

Place: Chennai  
Date : 23 July 2021

By order of the Board

Dr. Amar Agarwal  
Chairman & Managing Director  
DIN No. 00435684






**INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM FINANCIAL RESULTS**

**TO THE BOARD OF DIRECTORS OF  
DR. AGARWAL'S EYE HOSPITAL LIMITED**

1. We have reviewed the accompanying Statement of Unaudited Financial Results of **DR. AGARWAL'S EYE HOSPITAL LIMITED** ("the Company"), for the quarter ended 30 June 2021 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **DELOITTE HASKINS & SELLS**  
Chartered Accountants  
(Firm's Registration No. 008072S)



**Ananthi Amarnath**  
(Partner)  
(Membership No. 209252)